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Myotonic Dystrophy type 1 (DM1) is caused by the expansion of non-coding 
CTG repeats in the dystrophia myotonica-protein kinase gene. Mutant 
transcripts form CUG hairpins that sequester RNA-binding factors into 
nuclear foci, including Muscleblind-like-1 protein (MBNL1), which regulate 
alternative splicing and gene expression. To identify molecules that target 
toxic CUG transcripts in vivo, we performed a positional scanning 
combinatorial peptide library screen using a Drosophila model of DM1. The 
screen identified a D-amino acid hexapeptide (ABP1) that reduced CUG foci 
formation and suppressed CUG-induced lethality and muscle degeneration 
when administered orally. Transgenic expression of natural, L-amino acid 
ABP1 analogues reduced CUG-induced toxicity in fly eyes, and muscles. 
Furthermore, ABP1 reversed muscle histopathology and splicing 
misregulation of MBNL1 targets in DM1 model mice. In vitro, ABP1 bound to 
CUG hairpins and induced a switch to a single-stranded conformation. Our 
findings demonstrate that ABP1 shows anti-myotonic dystrophy activity by 











Myotonic Dystrophy type 1 (DM1, OMIM #160900) is an autosomal 
dominant disease caused by the expansion of a CTG trinucleotide repeat in 
the 3’ untranslated region (UTR) of the dystrophia myotonica protein kinase 
(DMPK) gene. Characteristic symptoms include myotonia, progressive 
muscle wasting, and cardiac conduction defects, among other systemic 
manifestations. The molecular mechanisms underlying DM1 pathogenesis 
are complex and affect a large number of cellular processes1. However, 
most data suggest that the main triggering event is a toxic gain-of-function 
of the expanded CUG RNA. CUG repeat expansions form double-stranded 
hairpins that are retained as inclusions within the nucleus. These hairpins 
recruit a number of transcription and splicing factors, including Muscleblind-
like 1 (MBNL1)2-6. Sequestration of MBNL1 originates a loss-of-function, 
which plays a key role in the development of DM1 symptoms. Mbnl1 
knockout mice reproduced typical features of DM1, and overexpression of 
Mbnl1 in a mouse model that expressed CTG repeats reversed these 
phenotypes7,8. CTG-repeat expression in mice caused misregulation of at 
least 156 alternative splicing events. Of these, 128 also occurred in Mbnl1 
knockout animals9-12. The splicing factor CUG-Binding Protein 1 (CUGBP1) is 
another key component in the development of DM1 phenotypes. CUGBP1 
antagonizes MBNL1 activity in the regulated use of alternative exons in a 
number of transcripts, and is abnormally upregulated in patients with DM1, 
further contributing to splicing misregulation13-15.  
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Mahadevan et al. provided the first in vivo proof-of-principle for a 
therapeutic strategy based on ablating toxic RNA molecules in DM116. They 
demonstrated that expanded CTG-induced effects could be reverted if CTG-
repeat transgene expression was interrupted in a DM1 mouse model. 
Several other groups developed synthetic molecules and (CAG)n 
oligonucleotides that disrupted MBNL1 interaction with expanded CUG 
repeats17-22. However, those approaches may not address all the 
pathological consequences of expanded CUG RNAs. Moreover, unspecific 
MBNL1-RNA binding inhibition could affect other normal MBNL1-dependent 
splicing events. Therefore, it would be desirable to identify molecules that 
target toxic repeats without interfering with cellular, non-pathological 
MBNL1-RNA interactions. 
Results 
In vivo screening of a combinatorial peptide library in Drosophila 
identified a hexapeptide that suppressed CUG toxicity  
The targeted expression of 480 interrupted CTG repeats, UAS-
i(CTG)480, to the Drosophila brain structure the Mushroom Bodies (MB) with 
the X-linked 103Y-Gal4 driver (103Y-Gal4/+; UAS-i(CTG)480/+) originates a 
female-specific, semilethal phenotype at pupal stage23. To screen for 
molecules that suppressed that phenotype, we used a positional scanning 
synthetic combinatorial library (PS-SCL) of D-amino acid hexapeptides24,25. 
The library comprised 120 peptide mixtures, each of them containing 
approximately 2.5 million individual hexapeptides (195; D-Cys was omitted 
from the mixture positions). Each mixture addressed a separate, single 
position of the hexamer sequence. The 120 peptide mixtures were tested 
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individually in vivo (80 µM) in nutritive media with 0.1% dimethyl sulfoxide 
(DMSO)23. The number of female flies that emerged was compared to 
DMSO-treated control individuals, and 28 peptide mixtures that significantly 
suppressed CUG-induced lethality were identified. Based on the screen 
results, 16 individual peptides were generated and evaluated (Supp. Table 
S1). The hexapeptide Ac-ppyawe-NH2 (ABP1; lower case one-letter code for 
D-amino acids) significantly suppressed lethality in a dose-dependent 
manner (Fig. 1A). The individual contribution of each amino acid in ABP1 
was determined using an alanine scanning, single substitution approach26. 
Each mutant peptide (mut1 to mut5; see Supp. Table S1) was evaluated for 
its effect on the viability of 103Y-Gal4/+; UAS-i(CTG)480/+ female flies. 
None of these peptides suppressed CUG-induced lethality, indicating that all 
amino acids in the original ABP1 sequence were necessary for its activity 
(Fig. 1B). To examine whether ABP1 could non-specifically reduce UAS-
i(CTG)480 transcription, we measured luciferase reporter activity in flies of 
the genotype Myosin heavy chain (MHC)-Gal4/+; UAS-luciferase/+ after 
treatment with DMSO or ABP1. The results revealed no significant 
differences in the luciferase signal (Fig. 1C). In addition, the levels of 
i(CUG)480 transcripts in MHC-Gal4/+; UAS-i(CTG)480/+ flies were measured 
by semi-quantitative RT-PCR. We detected no reduction in the amount of 
toxic RNA in ABP1-treated individuals (Supp. Fig. S1A-B).  
To confirm that ABP1 could suppress CUG-induced toxicity in 
muscles, we analyzed ABP1 activity on a muscle degeneration phenotype 
caused by the expression of i(CUG)480 in the indirect flight muscles (IFM) 
under the control of the MHC-Gal4 driver23,27. ABP1 increased total muscle 
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area in a dose-dependent manner up to 37.8% compared to DMSO-treated 
flies (Fig. 1D-I). 
Transgenic expression of ABP1 in Drosophila suppressed CUG-
induced phenotypes 
 In vivo ABP1 activity relied on its ability to diffuse through tissues 
and membranes, and to counteract CUG toxicity. To separate both 
properties, we performed tissue-specific expression of three transgenes that 
encoded ABP1-derivatives, UAS-ABP1f, UAS-ABP1r, and UAS-ABP1c. The 
UAS-ABP1f construct encoded a 10-mer peptide with a methionine and 
three spacer glycines followed by the forward sequence of a natural L-amino 
acid ABP1 variant; UAS-ABP1r encoded a similar peptide with the sequence 
of ABP1 reversed (thus mimicking the spatial disposition of the side chains 
of ABP1); and UAS-ABP1c encoded a 20-mer peptide that linearly linked 
UAS-ABP1f and UAS-ABP1r. When expressed alone, none of these 
transgenic lines had a phenotype. However, when crossed to flies that 
expressed i(CUG)480 in the eye under the control of the glass multiple 
reporter (GMR)-Gal4 driver, the UAS-ABP1r and UAS-ABP1c (but not UAS-
ABP1f) transgenes suppressed eye phenotypes (Supp. Fig. S2A-C). This 
confirmed ABP1 activity on CUG toxicity and indicated that the spatial 
conformation of the ABP1 side chains was important for in vivo activity.  
UAS-ABP1r and UAS-ABP1c also suppressed muscle degeneration in 
the IFM, with a 3.5-fold increase in total muscle area (Supp. Fig. S2D-F). 
This effect was ~9 times stronger than that observed upon oral 
administration. Therefore, improving the bioavailability of the peptide 
enhanced its activity. In all cases, coexpression of UAS-i(CTG)480 and UAS-
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GFP was used as control to guarantee comparable amounts of Gal4 protein 
available to activate each transgene. To rule out an effect of the transgenic, 
reverse forms of ABP1 on UAS-i(CTG)480 transcription, we measured 
luciferase reporter activity in flies of the genotype MHC-Gal4/+;UAS-
luciferase/UAS-ABP1r and compared it with MHC-Gal4/+;UAS-
luciferase/UAS-ABP1f flies. No significant differences in the luciferase signal 
were detected between genotypes (Supp. Fig. S1C). 
ABP1 bound to CUG repeats in vitro without displacing Muscleblind  
Binding of Muscleblind (Mbl) zinc finger domains to CUG repeats is 
strongly directed by the presence of aromatic residues28. The sequence of 
the ABP1 hexapeptide is also enriched in aromatic amino acids. We 
therefore explored whether ABP1 activity relied on a direct binding to toxic 
CUG-repeat RNAs, and a potential competition with Mbl for binding. Using 
an electrophoretic mobility shift assay, we analyzed the binding of a 
synthetic, fluorescently labeled 23-CUG-repeat (FAM-CUG23) RNA and a 4-
CUG-repeat (FAM-CUG4) RNA to ABP1. In these experiments, the peptide 
bound to both FAM-CUG23 and FAM-CUG4, and the interaction was 
reversed with excess non-labeled RNA (Fig. 2A, Supp. Fig. S3B). However, 
the affinity was lower for the shorter repeats. The alanine scanning mutant 
peptides (mut1 to mut5) did not bind to FAM-CUG23 (Supp. Fig. S3A). This 
demonstrated that a single amino acid change in ABP1 disrupted its ability 
to bind to synthetic CUG-repeats. Thus, in vitro RNA binding correlated with 
suppression of CUG-induced toxicity in vivo. A recombinant protein derived 
from the two zinc fingers of Drosophila Mbl (MblZF) also bound to CUG-
repeat RNA (Supp. Fig. S3C). However, in our experimental conditions both 
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ABP1 and MblZF formed complexes with the RNA that were unable to enter 
the gel, making qualitative and quantitative analyses of competition 
between ABP1 and MBLZF not feasible. In order to study the effect of ABP1 
on MblZF binding to FAM-CUG23, we used fluorescence polarization 
spectroscopy. In these experiments, both the peptide and the protein bound 
to the fluorescent RNA, increasing its polarization (Fig. 2B). The interaction 
was reversed with excess non-labeled RNA, which reduced fluorescence 
polarization to that of free FAM-CUG23. However, when FAM-CUG23 was 
simultaneously incubated with ABP1 and MblZF, no significant reduction in 
FAM-CUG23 polarization was observed. In contrast, an additive effect was 
detected. These results suggested that ABP1 and MblZF had different 
binding sites in the CUG RNA.  
ABP1 bound with higher affinity to CUG repeats than to other 
sequences 
ABP1 contains the fluorescent amino acid D-tryptophan. Changes in 
tryptophan fluorescence emission at 351 nm were detected upon ABP1 
binding to RNA and DNA sequences. ABP1 tryptophan fluorescence was 
quenched when bound to the following: an RNA sequence that included 19 
nucleotides (nt) from the 3’UTR of DMPK, followed by four CUG repeats 
(DMPK-CUG4); a single-stranded RNA sequence that included the 19-nt 
region of DMPK alone (DMPK); a perfect RNA hairpin with four CAG·CUG 
repeats (CAG·CUG4); a single-stranded DNA sequence that included the 19-
nt region of DMPK (DMPK); and a double-stranded DNA with four CTG 
repeats (CTG4). This indicated that ABP1 could bind to different types of 
nucleic acids. However, DMPK-CUG4 RNA showed the highest quenching 
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efficiency (Fig. 2C). Only the ABP1 interaction with CAG·CUG4 RNA showed 
a similar quenching rate, suggesting target selectivity for ABP1.  
ABP1 caused a switch from double-stranded to single-stranded 
conformation in the CUG RNA 
To study changes in RNA conformation induced by ABP1 we measured 
the circular dichroism (CD) of a 60 CUG-repeat RNA (CUG60) after 
incubation with increasing concentrations of the peptide. The CD spectrum 
of CUG60 alone showed a major peak at ~265 nm. Addition of ABP1, but 
not the ABP1 alanine-substituted peptides mut1 (Fig. 2D-E) and mut4 
(Supp. Fig. S4C), caused a concentration-dependent decrease in the CD 
signal. This indicated that ABP1 specifically induced a reduction in RNA base 
stacking. The addition of MblZF did not reverse this effect (Supp. Fig. S4A-
B). The observed CD signal reduction was not caused by partial 
denaturation or degradation of the RNA during the time course of the 
experiment (Supp. Fig. S4D). These results suggested that ABP1 promoted 
a relaxation in the secondary structure of CUG60.  
To confirm that ABP1 induced CUG-repeat RNA to change from a 
double-stranded to single-stranded conformation, we substituted a 
guanosine residue in a 23 CUG-repeat RNA with the adenosine analogue 2-
amino purine (2AP-CUG23). The 2-amino purine fluorescence is strongly 
quenched in a base-paired structure, but it increases 2-3 fold in a single-
stranded conformation29. When different concentrations of MblZF and ABP1 
were incubated with the RNA at molar ratios lower than 1:5, neither the 
MblZF protein nor the ABP1 peptide disrupted the double-stranded RNA 
conformation (Supp. Fig. S4E). However, at a molar ratio of 1:100 ABP1 
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caused a 2.9 fold increase in 2-AP fluorescence (Fig. 2F). This indicated a 
switch from predominantly double-stranded to predominantly single-
stranded conformation. In contrast, addition of DMSO alone, mut1 or mut4 
did not modify 2AP-CUG23 fluorescence, demonstrating the specificity of 
the effect. Because double-stranded CUG and single-stranded CUG RNAs co-
exist in vitro, and Muscleblind proteins are known to bind CUG hairpins3, 
these results explained the additive behavior of ABP1 and MblZF observed in 
our polarization experiments. 
ABP1 reduced CUG RNA foci formation and Muscleblind aggregation 
in Drosophila 
In vitro results suggested that ABP1 activity relied on its ability to 
reduce the formation of CUG RNA hairpins. To study whether the peptide 
effectively decreased the number of toxic double-stranded CUG molecules in 
Drosophila, which accumulate forming nuclear foci, we studied CUG RNA 
distribution in the IFM on longitudinal thorax sections of Mhc-Gal4/+; UAS-
i(CTG)480/+ flies that had been fed different concentrations of ABP1. Oral 
administration of the peptide significantly suppressed CUG foci formation at 
all concentrations assayed (Fig. 3A-D), indicating that ABP1 also inhibits 
double-stranded RNA formation in vivo. This reduction was accompanied by 
a redistribution of Mbl protein within the cells. In the absence of peptide, 
CUG expression caused Mbl to accumulate into nuclear aggregates (Fig. 
3E). However, ABP1 treatment induced a Muscleblind redistribution to a 
preferentially diffuse pattern, which also included the cytoplasm (Fig. 3F).  
ABP1 reversed missplicing and muscle histopathology in a DM1 
mouse model  
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To confirm the effect of ABP1 in mammals, we used transgenic DM1 
model mice that carry 250 (HSALR) or 5 (HSASR) CTG repeats in the 3’UTR of 
the human skeletal actin open reading frame30.  
A histological hallmark of both DM1 and HSALR muscle fibers is the 
presence of central nuclei30. Based on initial ABP1 toxicity analyses in wild-
type animals (FVB; see Supp. Table S3), we injected 0.5 µg (in 0.2% 
DMSO) or 10 µg (in 2% DMSO) of ABP1 into the right hind limb tibialis 
anterioris (TA) muscle. In both cases, ABP1 significantly reduced the 
percentage of fibers with central nuclei in 3 out of 5 HSALR mice (60% of the 
animals; Fig. 4A-C and 4F; and Supp. Table S4; referred to as “ABP1-
responsive animals”) one month after injection (a/i) compared to DMSO 
controls. Another characteristic of DM1 muscles is a reduction of functional 
Chloride Chanel-1 (ClC-1) protein. A loss of ClC-1 activity in the muscle 
membranes is the cause of myotonia30. Immunohistochemical studies of 
Clcn-1 levels on muscle sections of ABP1-treated (10 μg) mice showed a 
qualitatively evident increase in the amount of Clcn1 protein detected in 
80% of the animals 1 month a/i (Fig. 4D-E; Supp. Table S4). 
Alternative splicing is severely misregulated in DM1 patients and in 
HSALR mice11,12. We analyzed alternative splicing patterns in transcripts of 
two direct Mbnl1 targets: the muscle sarcoplasmic/endoplasmic reticulum 
Ca2+ ATPase (Serca1) and Fast skeletal muscle troponin T (Tnnt3). Exon 22 
of Serca1 is included in adult muscle, but excluded in neonatal, adult DM1, 
and mouse HSALR muscles31. Semi-quantitative RT-PCR on muscle tissues 
from FVB and DM1 mice showed that ABP1 injection (10 µg) in the TA of 
HSALR animals caused a significant increase in Serca1 exon 22 inclusion in 
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60% of the treated animals (mice 2, 3, and 4; Supp. Table S4). The degree 
of reversion to normal splicing was quantified in ABP1-responsive animals at 
two and four weeks a/i yielding a 25.9% and 38.3% increase in exon 22 
inclusion, respectively. At the later time point, we also detected a 14.7% 
increase in exon 22 inclusion in the DMSO-injected left limb of ABP1-
responsive animals injected with ABP1 in the right limb compared to 
animals that received DMSO in both limbs (Fig. 5). These results suggested 
that ABP1 had a systemic effect. A qualitative assessment of Tnnt3 
missplicing showed that ABP1 also reversed the splicing defects in HSALR 
animals 1 week a/i (40% of the animals), 2 weeks a/i (60% of the animals), 
and 4 weeks a/i (80% of the animals). Importantly, ABP1 did not change 
the splicing pattern of Serca1 or Tnnt3 transcripts in control FVB or HSASR 
mice. This demonstrated that ABP1 did not compromise Mbnl1 function in 
vivo. Finally, the peptide did not interfere with the activity of other 
alternative splicing factors, since it did not affect the Mbnl1-independent 
alternative splicing of F-actin-capping protein subunit beta (Capzb) exon 8, 
the regulation of which is unaffected in HSALR mice. Taken together, these 
results validate the potential of ABP1 as a suppressor of CUG-repeat RNA-
induced toxicity in mammals. 
.  
Discussion 
ABP1 efficiently suppressed CUG-induced phenotypes in three different 
Drosophila tissues: brain, muscle, and eye. Moreover, the peptide 
significantly reduced the number of CUG RNA foci and caused a Mbl 
subcellular redistribution in the fly muscle. Two findings confirmed the 
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specificity of ABP1 in vivo. First, ABP1 effects were dose-dependent in fly 
muscle, brain (oral administration), and eyes (transgenic expression). 
Second, alanine-substituted peptide derivatives of ABP1 had no effect on 
CUG-induced lethality in flies. Thus, CUG toxicity was specifically 
suppressed by ABP1, and each amino acid in the peptide sequence was 
necessary. Moreover, the suppression of CUG-induced phenotypes by 
transgenic expression of a reverse ABP1 sequence (ABP1r and ABP1c) 
indicated that the in vivo activity of ABP1 resided in the spatial disposition 
of its side chains. Interestingly, ABP1 has two aromatic amino acids in its 
sequence (tryptophan and tyrosine). The side chains of aromatic amino 
acids in a number of proteins have been found to be critical for enabling 
RNA binding, including the CCCH-type zinc finger protein Tis11, and 
MBNL128, 32. 
Both the fly and mouse models used in this work expressed CUG-repeat 
transcripts independently of DMPK. Therefore, in vivo, ABP1 could target 
either the toxic CUG-RNA or a pathogenic target downstream of the 
expanded repeats. However, the downstream effects of CUG-repeat RNA 
expression are likely to vary among different tissues. The fact that ABP1 
suppressed CUG-repeat associated toxicity in at least three different fly 
tissues indicated that its activity was independent of environmental factors, 
and only depended on the toxicity of CUG-repeat RNA. This notion is 
supported by our in vitro experiments, which demonstrate that ABP1 
directly binds to CUG-repeat RNAs, and suggest that ABP1 might be 
effective to treat other diseases caused by CUG expansions.  
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Based in our in vitro and in vivo results, in this study we propose that 
the molecular mechanism underlying ABP1 activity relies on the induction of 
a conformational shift in CUG secondary structure (see Supp. Fig. S5). 
Causing a switch from predominantly double-stranded CUG RNA to 
predominantly single-stranded CUG molecules in the nuclei should, in 
principle, restore homeostasis to CUG-expressing cells. Our in vitro results 
suggested that ABP1 did not prevent MblZF from binding to CUG hairpins. In 
contrast, their binding to the CUG repeats was additive, most likely because 
they bind and stabilize different co-existing conformations of the RNA. 
Importantly, the Mbnl1 splicing function on its direct targets Serca1 and 
Tnnt3 was partially restored in ABP1-treated HSALR mice. This demonstrates 
that the suppression of CUG-dependent phenotypes and recovery of Mbnl1 
activity can be achieved without directly competing with Muscleblind binding 
to CUG repeats, but by reducing the fraction of double-stranded CUG RNA 
from the cellular pool of toxic RNA, hence preventing sequestration of the 
protein, which requires CUG RNA hairpins. This is a novel mechanism that 
contrasts with that of other recently characterized molecules that target the 
binding of MBNL1 to toxic RNAs17-22,33. Disrupting Muscleblind binding to 
RNA could affect its function as a splicing factor in non-CUG expressing 
cells. Our results suggest that ABP1 does not interfere with natural Mbnl1 
splicing activity, as Tnnt3 and Serca1 transcripts were not misspliced in FVB 
and HSASR mice. Moreover, ABP1 does not alter the function of other 
splicing factors, because the Mbnl1-independent transcript Capzb was not 
affected by ABP1 treatment.  
An important advantage of ABP1 is that it is composed of D-amino acids, 
which are not recognized by proteases. This, coupled with its small 
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molecular weight (<900 Da), confers ABP1 with a potentially higher 
systemic bioavailability compared to larger L-amino acid peptides. The 
protease resistance of ABP1 also confers stability in the organism, and 
therefore it may exhibit long-lasting effects. This could account for our 
observation that the reversal of splicing defects and muscle histopathology 
in mice lasted for at least four weeks after one single injection. Based on 
our results, we propose that ABP1 represents a promising approach in the 
generation of new effective treatments for DM1.  
Materials and Methods 
Drosophila stocks. MHC-Gal4 flies were a gift of Dr. Eric Olson, University of 
Texas, Southwestern Medical Center, Texas. UAS-ABP1f, UAS-ABP1r, and 
UAS-ABP1c flies were generated with synthetic DNA oligonucleotides 
(Metabion, Germany; Supp. Table S2) cloned into the Drosophila pUAST 
vector. Transgenes were microinjected into y1w1118 embryos (BestGene; CA, 
USA). Other fly stocks were described in23. 
Eye and muscle histology. SEM imaging was described in23. Ten-day old 
Drosophila thoraces were embedded in Epon for transversal, semi-thin 
sectioning34. Muscle area was quantified by binarizating images (equal 
dimensions) and quantifying pixels (%) within muscle tissue with Image-J 
software. Frozen sections (10 μm) of mouse TA were stained with H&E or 
immunostained using antibody against the ClC-1 C-terminus (Alpha 
Diagnostic, San Antonio, TX; 1:50) as described in7. For comparison of 
treated and untreated muscle, sections were stained on the same slide, and 
images were obtained using the same settings with a confocal microscope 
(Leica TCS SP2 DM-R).  
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MblZF expression and purification. DNA encoding 98 amino acids of 
Drosophila Mbl was amplified by PCR from OrR flies (Supp. Table S2) and 
cloned into the pET-15b expression vector. Transformed E. coli BL21 (DE3) 
cells, grown in LB medium supplemented with 2% glucose and 50 μM ZnCl2, 
were induced with 1 mM of IPTG for 2 h at 16ºC. Cells were collected, 
resuspended (50 mM Tris-HCl pH 7.5, 250 mM NaCl, 50 μM ZnCl2, 10% 
glycerol, and 1 mM DTT), and sonicated. MblZF was purified from the 
soluble fraction in an FPLC ÄKTATM with 1ml HisTrapHP columns (Amersham 
Biosciences).  
Fluorescence polarization. CUG RNA (23 repeats) labeled with 
carboxyfluorescein (FAM-CUG23; 6 nM) was incubated with ABP1, MblZF, or 
DMSO (free RNA controls) in binding buffer (25 mM Tris-HCl pH 7.5, 100 
mM NaCl, 5 mM MgCl2, 50 μM ZnCl2, and 10 % glycerol) on ice (20 min) in 
the dark. Polarization was measured in a Multilabel Counter (excitation filter 
FP480, emission filter FP535).  
Fluorescence electrophoretic mobility shift assay. FAM-CUG23 and FAM-
CUG4 RNAs were heated at 70ºC (5 min), diluted (60 nM) in binding buffer, 
kept at 37ºC (5-10 min), incubated with ABP1, MblZF or DMSO (free RNA 
controls) at 37ºC (20 min), and loaded into pre-run 6% polyacrylamide 
non-denaturing gels. Electrophoresis at 4ºC (~1 h) at 150-200V was 
followed by visualization with 520 BP/526 SP filters on a Typhoon 9400 
scanner (Amersham). 
Tryptophan fluorescence quenching. Fluorescence of ABP1 (5 μM in binding 
buffer), incubated with increasing concentrations of DNA or RNA, was 
measured at room temperature with a Jasco FP6500 spectrofluorimeter 
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(excitation 290 nm, emission 351 nm). Emission measurements were 
normalized to those of peptide alone. At least two measurements were 
taken per titration point.  
2-aminopurine fluorescence. 2AP-CUG23 RNA (1 μM in binding buffer) was 
heated at 90ºC (3 min), placed on ice, and fluorescence was measured35. 
Increasing amounts of peptide and protein were added and fluorescence 
changes were measured three times per titration point. Emissions (375 nm) 
of peptide (or protein) alone were subtracted from RNA spectra. 
Measurements were normalized by dividing the emission values at 375 nm 
by those of 2AP-CUG23 RNA alone.  
Transgenic mice and peptide administration. Mouse handling and 
experimental procedures conformed to the European law of Laboratory 
Animal Care and experimentation (2003/65/CE). Transgenic HSALR (line 
20b) and HSASR (line 05) mice were described30. FVB mice were used as 
wild-type animals. The right and left hind limb TAs of five five-week old 
gender-matched mice were injected intramuscularly with 10 μl of peptide or 
DMSO (internal control), or DMSO was injected on both sides (HSALR 
controls). One, two, or four weeks after injection, animals were sacrificed 
and TAs were dissected in two equal pieces for histological and splicing 
analyses. 
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Figure 1. ABP1 suppressed i(CTG)480-induced phenotypes in a dose-
dependent manner. (A) Number of 103Y-Gal4/+; UAS-i(CTG)480 female 
flies emerged after ABP1 treatment relative to DMSO-treated controls. ABP1 
concentrations of 40 μM, 80 μM and 125 μM caused increments in the 
number of emerged flies of 2.5 (n=120), 6.7 (n=180), and 8.3 (n=120) 
respectively, compared to DMSO-treated controls. ABP1 at 250 µM caused a 
drop in female viability, suggesting a toxic effect (n=120). (B) Five mutant 
derivates of ABP1 (mut1-5), with single alanine substitutions, did not 
suppress i(CTG)480 toxicity (n=60). (C) ABP1 did not reduce the expression 
of luciferase reporter in MHC-Gal4/+; UAS-luciferase/+ flies. The average 
luciferase light emission is shown for 9-10 replicates (total n=27-30 flies). 
(D-H) Representative bright field microscopy images of transversal sections 
of resin-embedded adult IFM of MHC-Gal4/+;UAS-i(CTG)480/+ flies that had 
been (D) treated with DMSO or (E–H) with ABP1. ABP1 (62.5 μM, 125 μM 
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and 250 μM) increased the muscle area relative to DMSO-treated flies 
(quantified in I) and fiber loss was reduced (arrowhead). ABP1 at 500 µM 
enhanced the phenotype, indicating a toxic effect. All graphs show the 
mean and SEM except graph (A), which shows the sum of all replicates. * 
indicates p-value<0.05, *** indicates p-value <0.0001.  
Figure 2. ABP1 bound to CUG repeats and caused a switch in CUG 
secondary structure. (A) Electrophoretic mobility shift assay using a FAM-
labeled 23 CUG-repeat RNA (FAM-CUG23; 60 nM) and a FAM-labeled 4 
CUG-repeat RNA (FAM-CUG4; 60 nM). The gel shows a decrease in the free 
RNA band intensity. Binding of ABP1 (2.5 mM) to FAM-CUG23 was stronger 
than to CUG4. A non-labeled CUG RNA (6 µM) competed both interactions. 
(B) Fluorescence polarization of FAM-CUG23. Both ABP1 (10 μM) and MblZF 
(2.5 μM) caused polarization of the RNA (6 nM). Co-addition of ABP1 and 
MblZF at non-saturating concentrations did not reverse the RNA 
polarization, but showed an additive effect. (C) Tryptophan fluorescence 
quenching (FQ) of ABP1. ABP1 (5 μM) was incubated with RNA (DMPK-
CUG4, CAG·CUG4, DMPK) or DNA (CTG4) molecules at 2.5 μM, 5 μM, 7.5 
μM, 10 μM, and 12.5 μM. The slopes of the curves obtained from plotting 
fluorescence emission values at 351 nm for each titration point were 
normalized to DMPK-CUG4 and are represented in bars as a measure of the 
FQ efficiency. (D) The circular dichroism (CD) spectrum of a 60 CUG-repeat 
RNA (CUG60; 1 μM) showed a major peak at 265 nm. This peak was 
reduced when the RNA was incubated with ABP1 at 0.1 μM (pink), 0.5 μM 
(dark blue), 1 μM (green), 10 μM (red), and 20 µM (light blue). (E) This 
change did not occur when CUG60 (red) was incubated with mutant 
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derivatives of ABP1, including mut1 at 0.5 μM (dark blue) and 1 μM (green). 
(F) 2AP-fluorescence measurements of the 2AP-CUG23 RNA (1 μM). The 
addition of 100 μM peptide destabilized the hairpin, and caused a 2.9 fold 
increase in the fluorescence intensity. MblZF, DMSO, mut1, and mut4 
peptides did not cause changes at the same concentration. All graphs show 
the mean and SEM values for at least four (B) or two measurements (C). * 
indicates p-value<0.05. 
Figure 3. ABP1 reduced the number of CUG RNA foci in Drosophila 
and released Mbl from nuclear aggregates. (A-C) Representative 
fluorescent in situ detection of i(CUG)480 transcripts in the IFM on thorax 
sections of MHC-Gal4/UAS-GFP (control; A) or MHC-Gal4/+; UAS-
i(CTG)480/+ (B, C) flies orally treated with 0.12% DMSO (A, B) or different 
concentrations of ABP1 (250 µM is shown as an example in C). ABP1 
treatment significantly reduced the number of CUG RNA foci per section at 
all concentrations tested (D). (E, F) Immunofluorescent detection of Mbl 
(green) in the IFM of DMSO-treated (0.12%; control) and ABP1-treated 
(250 µM) MHC-Gal4/+; UAS-i(CTG)480/+ flies. Oral administration of ABP1 
caused a switch in Mbl cellular distribution from aggregated (control; E) to 
disperse (treated; F). Nuclei are counterstained with DAPI (blue) in E-F. The 
graph in (D) shows the mean and SEM from ABP1-responsive animals. * 
indicates p-value<0.05, ** indicates p-value<0.0005.  
Figure 4. ABP1 suppressed histological defects in DM1 mouse 
muscles.  Intramuscular injection was carried out in the hind limb TA 
muscles of mice that expressed human skeletal actin flanked by 250 CTG 
repeats (HSALR)30 or wild-type controls (FVB). (A-C) Representative 
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histological TA sections from animals injected with 0.2 or 2% DMSO (control 
left limb in HSALR and right limb in FVB; A and C), or 0.5 or 10 μg of ABP1 
(right limb in HSALR; B), respectively. The images show a significant 
decrease in the percentage of cells with central nuclei 1 month after ABP1 
injection (F). (D, E) Immunofluorescent detection of Clcn1 protein (green) 
in HSALR mouse TA sections 1 month a/i. In 2% DMSO-treated limbs (D) the 
Clcn1 signal was almost absent, whereas the fluorescent signal was 
significantly stronger in the contralateral ABP1-treated limb (10 μg) (E). 
Nuclei are counterstained with DAPI (blue) in D-E. The graph in (E) shows 
the mean and SEM from ABP1-responsive animals. * indicates p-
value<0.05.   
Figure 5. ABP1 suppressed splicing defects in DM1 mouse muscles. 
ABP1 (10 μg) was injected intramuscularly in the right hind limb TA of 
HSALR mice, animals that expressed short (5) CTG repeats (HSASR)30 or 
wild-type animals (FVB). Semiquantitative RT-PCR performed 1 week a/i 
(A), 2 weeks a/i (B), and 4 weeks a/i (C) showed that ABP1 partially 
reversed splicing defects in muscle transcripts of Serca1 (quantified in D-E) 
and Tnnt3 genes in HSALR mice. ABP1 did not change the splicing patterns 
of Serca1 and Tnnt3 in FVB or HSASR strains. A muscular transcript that 
undergoes Mbnl1-independent alternative splicing and is unaffected in this 
model, Capzb, was not altered by ABP1 injection in any strain. Each pair of 
lanes in the gels represent the left, 2% DMSO-injected leg (-) and the right, 
10 μg ABP1-injected leg (+) of the same animal. All graphs show the mean 
and SEM from ABP1-responsive animals. * indicates p-value<0.05. 
 





